Tag Archives: chemotherapy

Chemotherapy with Alimta: Putting More Gold in the Gold Standard

chemotherapy with Alimta

A new Italian study suggests there may be a more effective way to deliver mesothelioma chemotherapy with Alimta. Chemotherapy with Alimta (pemetrexed) is the gold standard treatment for malignant pleural mesothelioma. But fewer than 40 percent of mesothelioma patients see improvement when they receive the drug by standard infusion. Now, researchers in biotechnology and nanomedicine think they may have found a way around the limits of chemotherapy with Alimta. Tiny particles of gold may be the answer. Why Chemotherapy with Alimta Does Not Always Work Even though most mesothelioma patients receive chemotherapy with Alimta at some point, it is usually only moderately effective. That is because pemetrexed is a highly potent drug that can cause deadly side effects at high doses. … Continue reading Chemotherapy with Alimta: Putting More Gold in the Gold Standard »

Doctor Attitude Keeps Some Patient from Mesothelioma Chemotherapy

chemotherapy for mesothelioma

A new study suggests that some patients are missing out on chemotherapy for mesothelioma because their doctors do not believe it will work. Doctor “nihilism” – the idea that life is meaningless anyway – was the top reason that 20+ percent of pleural mesothelioma patients did not get the care that might have helped them. In other cases, patients were simply never referred to a cancer doctor who could prescribe chemotherapy for mesothelioma. Doctor Attitudes and Chemotherapy for Mesothelioma The Australian study is based on surveys with 107 doctors and 19 nurses. Most respondents were either lung specialists or cancer doctors. They completed the surveys in 2014. The surveys show that most of the doctors (90%) think at least one … Continue reading Doctor Attitude Keeps Some Patient from Mesothelioma Chemotherapy »

Researchers Name Six Top Mesothelioma Survival Factors

Certain factors lead to longer mesothelioma survival

Researchers at the University of Pittsburgh have named what they say are the top six mesothelioma survival factors. According to their new study, patients with one or more of these factors tend to have better mesothelioma treatment outcomes and live longer. Malignant mesothelioma – also called asbestos cancer – is one of the deadliest forms of cancer. It starts on internal membranes and spreads quickly. There is no cure and the disease is very hard to slow down. Many mesothelioma patients die within 12 to 18 months. But there are cases of much longer mesothelioma survival. Some patients have even lived for decades after mesothelioma treatment. The Pittsburgh researchers wanted to find the mesothelioma survival factors shared by the longest … Continue reading Researchers Name Six Top Mesothelioma Survival Factors »

Treatment for Pericardial Mesothelioma: Chemotherapy is Best

treatment for pericardial mesothelioma

Some of the nation’s top cancer researchers say chemotherapy is the best treatment for pericardial mesothelioma.  Even surgery does not extend survival as well as chemotherapy. Doctors at the University of Texas reached that conclusion after studying more than 100 cases of pericardial mesothelioma. Surgery is still the most common treatment for pericardial mesothelioma. But the new research suggests that chemotherapy may be better. In the study, chemotherapy and cancer spread were the only factors that seemed to impact mesothelioma survival. What is Pericardial Mesothelioma? Malignant mesothelioma tumors grow on the linings around internal organs. The most common type is pleural mesothelioma which grows near the lungs. Peritoneal mesothelioma on the abdominal lining is the second most common type. Pericardial … Continue reading Treatment for Pericardial Mesothelioma: Chemotherapy is Best »

Chemotherapy for Mesothelioma May Work Better with TroVax

vaccine added to chemotherapy for mesothelioma

UK researchers say a cancer vaccine called Trovax has the potential to boost the power of chemotherapy for mesothelioma. Chemotherapy is the main treatment for malignant pleural mesothelioma. Mesothelioma is a cancer of the lung lining caused by asbestos exposure. It is very hard to treat. Even people who have chemotherapy for mesothelioma do not usually live more than two years after diagnosis. Mesothelioma researchers are always looking for ways to improve chemotherapy for mesothelioma. It is often combined with other treatments like surgery, radiation or immunotherapy. Now, scientists think adding TroVax to mesothelioma chemotherapy may be another good option. What is the TroVax Cancer Vaccine? The TroVax cancer vaccine is made by UK-based Oxford BioMedica. It contains an altered … Continue reading Chemotherapy for Mesothelioma May Work Better with TroVax »

Faster Mesothelioma Chemotherapy Deemed “Safe and Feasible”

faster mesothelioma chemotherapy

Researchers in The Netherlands say it may be possible to deliver faster mesothelioma chemotherapy without doing any additional damage to the kidneys. If they are right, it could make mesothelioma treatment more accessible and convenient for patients. Most malignant mesothelioma patients will have chemotherapy. The most common type of chemotherapy is by infusion. Each session takes several hours. Every mesothelioma patient undergoing chemotherapy faces the possibility of kidney damage. That possibility can even limit how much medicine doctors can use. But a new Dutch study finds that faster mesothelioma chemotherapy may be as safe for the kidneys as standard chemotherapy. Analyzing Faster Mesothelioma Chemotherapy The study included 230 lung cancer patients who had chemotherapy. Some of the study subjects had … Continue reading Faster Mesothelioma Chemotherapy Deemed “Safe and Feasible” »

Belgian Mesothelioma Survival Study

mesothelioma survival study

A new Belgian mesothelioma survival study contains important insights for patients and doctors. Cancer center researchers did the study with data from the Belgian Cancer Registry. It includes more than 1400 patients. They received mesothelioma diagnosis between 2004 and 2012. The analysis is similar to past mesothelioma research. It shows the longest-surviving patients are the ones who have chemotherapy. Surgery patients also live longer. The third longer-living group are patients treated at experienced cancer centers. Mesothelioma Survival and Treatment The mesothelioma survival study asks what kinds of patients live longest and why. Researchers had to first see what treatments most patients receive. They found that most mesothelioma patients have chemotherapy. Chemotherapy usually includes pemetrexed (Alimta) and cisplatin. This is the … Continue reading Belgian Mesothelioma Survival Study »

More Support for Novel Mesothelioma Drug Delivery System

Pharmaceutical researchers working on a way to make the most popular mesothelioma drug more effective have found more evidence that fat may be the answer. The team at Zagazig University in Egypt and Tokushima University in Japan have developed a fat-based coating for the antifolate drug pemetrexed (Alimta) that may help improve outcomes for patients. Pemetrexed is currently the only drug approved specifically to treat malignant mesothelioma and most patients will receive it at some point. Even so, like most mesothelioma therapies, pemetrexed is only marginally effective, in part because the dose has to be limited to avoid serious side effects. The new drug delivery system was designed to get around this problem by encapsulating molecules of pemetrexed in tiny … Continue reading More Support for Novel Mesothelioma Drug Delivery System »

Scrubbed Trial May Not Be the End for Mesothelioma Drug

The makers of the once-promising experimental mesothelioma drug defactinib have announced that they will stop a clinical trial of the drug early because, by itself, it does not appear to help. But this may not be the end of the road for defactinib in mesothelioma treatment. Defactinib (VS-6063) had been the leading compound for its manufacturer, Boston-based Verastem. While standard mesothelioma chemotherapy drugs like pemetrexed, cisplatin, gemcitabine and vinorelbine can sometimes shrink mesothelioma tumors, they also increase the percentage of stem cells which can give rise to new cancer. Defactinib was designed to help keep malignant mesothelioma patients from relapsing by inhibiting a crucial signaling pathway (FAK) inside the stem cells. Early studies were encouraging, but a recent review of … Continue reading Scrubbed Trial May Not Be the End for Mesothelioma Drug »

Long Term Mesothelioma Survival with Immune System Activation

A small group of Australian mesothelioma patients have reportedly lived more than twice as long as expected with a combination of standard chemotherapy and immune system manipulation with the CD40 protein. The CD40 protein plays a role in a broad range of immune and inflammatory responses in the body. Studies in mice have found that activating CD40 with an activating antibody may work “synergistically” with chemotherapy drugs to fight cancer. To see whether CD40 activation could produce a similar response in human patients, researchers with the University of Western Australia and Sir Charles Gairdner Hospital in Perth recruited 15 malignant pleural mesothelioma patients in the early stages of the disease. The patients all received both standard chemotherapy (pemetrexed and cisplatin) … Continue reading Long Term Mesothelioma Survival with Immune System Activation »